Esparza J, Bhamarapravati N
WHO-UNAIDS HIV Vaccine Initiative, Health Technology and Pharmaceuticals, WHO, Geneva, Switzerland.
Lancet. 2000 Jun 10;355(9220):2061-6. doi: 10.1016/S0140-6736(00)02360-6.
An HIV-1 vaccine offers the best long-term hope to control the AIDS pandemic, especially in less-developed countries. To ensure its future availability we need to increase our research efforts today, including clinical trials. Although small-scale clinical trials of HIV-1 vaccines have been underway since 1987, the first phase III efficacy trials started only recently in the USA and Thailand. Initial results from these trials will be available within the next 2-3 years, and we must start planning now how vaccines should be used if found to be effective. In the meantime, the continuing promotion of the parallel development and assessment of other candidate vaccines is important. Financial mechanisms should also be developed as an incentive to industry and to ensure equitable distribution of future vaccines in less-developed countries. Moreover, a concerted effort is needed to ensure the development and future availability of appropriate vaccines for Africa.
一种HIV-1疫苗为控制艾滋病大流行带来了最有希望的长期解决方案，尤其是在欠发达国家。为确保其未来可得，我们现在需要加大研究力度，包括开展临床试验。尽管自1987年以来一直在进行HIV-1疫苗的小规模临床试验，但首个三期疗效试验最近才在美国和泰国启动。这些试验的初步结果将在未来两到三年内得出，我们必须现在就开始规划如果疫苗被证明有效应如何使用。与此同时，持续推动其他候选疫苗的并行研发和评估很重要。还应建立财务机制，以激励行业并确保未来疫苗在欠发达国家的公平分配。此外，需要共同努力确保为非洲研发并在未来提供合适的疫苗。
